DOCUMENT

10 | InTouch AUTUMN 2025 A JOURNEY OF HOPE Above: Ollie receiving his weekly infusion. Ollie relaxing with his French bull dog, Shadow. To speak to us about leaving a gift in your will, please email info@mda.org.nz We have been helping Kiwi families for more than 60 years and by making a bequest, you are ensuring the sustainability of our organisation so that we can continue to be there for generations to come. Any bequest, no matter what size, will directly help those living with muscle wasting neuromuscular conditions, and enable us to continue our work within your community. Your good will benefits families The Trial – Mission by Sarepta Therapeutics led by Dr Gina O'Grady A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants with Duchenne Muscular Dystrophy (DMD)”. Summary: Part 2 (dose finding and dose comparison) will evaluate the efficacy and safety of the high doses (100 mg/kg and 200 mg/kg) of eteplirsen compared with that of the 30 mg/kg dose of eteplirsen, in approximately 144 participants with genetically confirmed deletion mutations amenable to treatment by skipping exon 51. bloodwork, making the process physically and emotionally demanding. We are now nearing the end of this long and challenging medical trial. While the journey has been filled with uncertainty, setbacks, and difficult moments, it has also been a journey of hope, resilience, and determination. We don’t yet know what the future holds, but we do know one thing—our boys are fighting, and we will continue to fight alongside them. The research, the treatments, and the trials all mean something bigger than just our family; they represent hope for all families battling Duchenne muscular dystrophy. Continued from previous page.